早期滤泡性淋巴瘤累及野放疗后系统治疗的随机试验:TROG 99.03
多中心随机对照试验纳入150例I-II期低级别滤泡性淋巴瘤患者,比较单纯30 Gy累及野放疗(A组)与放疗联合6周期CVP或R-CVP(B组)。中位随访9.6年,B组无进展生存期优于A组(HR 0.57,95%CI 0.34-0.95,P=0.033),10年无进展生存率分别为59%和41%。
要点
- 放疗后联合系统治疗可显著改善早期滤泡性淋巴瘤的无进展生存期(HR 0.57,P=0.033)。
- B组中接受R-CVP者较同期A组患者无进展生存期明显更优(HR 0.26,95%CI 0.07-0.97,P=0.045)。
- 总生存期两组无显著差异(P=0.40),10年总生存率B组95%、A组87%。
核心结论
- 累及野放疗后联合R-CVP系统治疗减少了放疗野外的复发,并显著改善了无进展生存期。
- 在早期滤泡性淋巴瘤中,放疗后接免疫化疗比单纯放疗更有效。
研究设计与样本
- 多中心随机对照试验,2000年至2012年纳入150例经分期CT和骨髓活检确认的I-II期低级别滤泡性淋巴瘤患者,每组75例。
- A组接受30 Gy累及野放疗;B组接受累及野放疗联合6周期环磷酰胺、长春新碱和泼尼松龙(CVP),自2006年起B组加用利妥昔单抗(R-CVP),其中44例分配至CVP、31例分配至R-CVP。
- 18F-氟脱氧葡萄糖-正电子发射断层扫描(PET)非强制,48%患者接受了PET分期。
主要发现
- 中位随访9.6年(范围3.1至15.8年),B组无进展生存期优于A组(风险比0.57,95%CI 0.34至0.95,P=0.033)。
- B组和A组的10年无进展生存率分别为59%(95%CI 46%至74%)和41%(95%CI 30%至57%)。
- B组中接受R-CVP者较同期A组患者无进展生存期明显更优(风险比0.26,95%CI 0.07至0.97,P=0.045)。
- 受累区域较少(P=0.047)和PET分期(P=0.056)与更好的无进展生存期相关。
- 组织学转化在B组和A组分别发生4例和10例(P=0.1);A组死亡10例,B组死亡5例,但总生存期无显著差异(P=0.40;10年总生存率分别为95%和87%)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Follicular lymphoma (FL) is curable by involved-field radiotherapy (IFRT) in < 50% of patients with stage I to II disease. We hypothesized that adding systemic therapy to IFRT would improve long-term progression-free survival (PFS). PATIENTS AND METHODS: A multicenter randomized controlled trial enrolled patients with stage I to II low-grade FL after staging computed tomography scans and bone marrow biopsies. 18F-labeled fluorodeoxyglucose-positron emission tomography (PET) was not mandatory. Patients were randomly assigned to either arm A (30 Gy IFRT alone) or arm B (IFRT plus six cycles of cyclophosphamide, vincristine, and prednisolone [CVP]). From 2006, rituximab was added to arm B (R-CVP). RESULTS: Between 2000 and 2012, 150 patients were enrolled, 75 per arm. In arm B, 44 patients were allocated to receive CVP and 31 were allocated to receive R-CVP. At randomization, 75% had stage I, the median age was 57 years, 52% were male, and 48% were PET staged. With a median follow-up of 9.6 years (range, 3.1 to 15.8 years), PFS was superior in arm B (hazard ratio, 0.57; 95% CI, 0.34 to 0.95; P = .033). Ten-year PFS rates were 59% (95% CI, 46% to 74%) and 41% (95% CI, 30% to 57%) for arms B and A, respectively. Patients in arm B who received R-CVP had markedly superior PFS compared with contemporaneous patients in arm A (hazard ratio, 0.26; 95% CI, 0.07 to 0.97; P = .045). Fewer involved regions ( P = .047) and PET staging ( P = .056) were associated with better PFS. Histologic transformation occurred in four and 10 patients in arms B and A, respectively ( P = .1). Ten deaths occurred in arm A versus five in arm B, but overall survival was not significantly different ( P = .40; 87% and 95% at 10 years, respectively). CONCLUSION: Systemic therapy with R-CVP after IFRT reduced relapse outside radiation fields and significantly improved PFS. IFRT followed by immunochemotherapy is more effective than IFRT in early-stage FL.
引用
- MacManus M, Fisher R, Roos D, et al. Randomized Trial of Systemic Therapy After Involved-Field Radiotherapy in Patients With Early-Stage Follicular Lymphoma: TROG 99.03. J Clin Oncol. 2018. PMID: 29975623. doi:10.1200/JCO.2018.77.9892
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。